Streetbeat News

Analyst Ratings

CMCSA

Comcast (NASDAQ:CMCSA) has been analyzed by 4 analysts in the last three months, showing a mix of opinions with 1 bullish and 3 indifferent ratings. The average 12-month price target is $48.25, indicating a slight upward trend. Comcast's financial health is strong, with a market capitalization above industry averages, a revenue growth rate of 2.29%, a net margin of 10.43%, an ROE of 3.94%, an ROA of 1.24%, and a debt-to-equity ratio of 1.17. The company's diverse operations include its core cable business, NBCUniversal, and Sky.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 12:00 pm

JELD

Analysts have diverse views on JELD-WEN Holding (NYSE:JELD), with recent ratings being indifferent. The average 12-month price target has risen to $19.75, up 18.48% from $16.67. Analysts from Loop Capital, Stifel, Goldman Sachs, and Barclays have adjusted their price targets, reflecting a cautiously optimistic outlook. JELD-WEN's financials show a mix of strong net margin and ROE but a concerning revenue decline and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 12:00 pm

DECK

20 analysts have recently updated their ratings on Deckers Outdoor (NYSE:DECK), showing a diverse range from bullish to bearish. The average 12-month price target has increased by 14.78% to $828.35. Analysts have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Deckers Outdoor, known for brands like UGG and Teva, has shown strong financial performance with a revenue growth of 15.95%, a net margin of 24.99%, and an ROE of 20.0%. The company's market capitalization, however, falls below industry benchmarks.

Portfolio Pulse from Benzinga Insights

February 15, 2024 | 12:00 pm

MLTX

Wolfe Research analyst Andy Chen initiates coverage on MoonLake (NASDAQ:MLTX) with an Outperform rating, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 12:00 pm

CRSP

Wolfe Research analyst Andy Chen initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Peer Perform rating, indicating a neutral outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:58 am

ALNY

Wolfe Research analyst Andy Chen initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Peer Perform rating, indicating a neutral outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:56 am

MTRN

Materion Corporation projects its adjusted earnings per share (EPS) for fiscal year 2024 to be in the range of $6.10 to $6.50, compared to the analyst estimate of $6.29.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:49 am

KYMR

Wolfe Research analyst Andy Chen initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Peer Perform rating, indicating a neutral outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:45 am

LYFT

UBER

On February 14th, U.S. stock markets closed higher, with significant gains in Lyft and Uber after Lyft beat profit estimates and Uber announced a $7 billion share buyback plan. U.S. inflation decreased to 3.1% in January. Asian and European markets also saw gains, while commodities like crude oil and gold experienced mixed movements. The Dow Jones, S&P 500, and Nasdaq all closed higher.

Portfolio Pulse from Akanksha Bakshi

February 15, 2024 | 11:44 am

ROIV

Wolfe Research analyst Andy Chen initiates coverage on Roivant Sciences (NASDAQ:ROIV) with an Outperform rating and a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 11:41 am